Retatrutide

Retatrutide is an investigational once-weekly peptide developed by Eli Lilly that acts as a triple agonist of three receptors at once: GLP-1, GIP, and glucagon. It is currently in late-stage clinical research and has not yet received regulatory approval. It is one of the most-anticipated next-generation metabolic peptides because of the unusually large weight-loss numbers observed in its phase 2 trial.

Semaglutide pulls one lever. Tirzepatide pulls two. Retatrutide pulls three. The third lever — glucagon — is interesting because glucagon increases energy expenditure (the rate your body burns calories), not just appetite control. Combining all three is the leading bet from major pharmaceutical research on how to push weight-loss results beyond what GLP-1/GIP can do alone. Online, it is described as the 'big one to watch' in the GLP-1 era.

Retatrutide activates the GLP-1 receptor (satiety, insulin), the GIP receptor (insulin response, adipose function), and the glucagon receptor (hepatic glucose handling, lipolysis, thermogenesis). The glucagon component is what distinguishes it from dual agonists: instead of only reducing energy intake, it appears to also increase energy expenditure. Balancing glucagon activity is the challenge, since unopposed glucagon can raise blood sugar — but the GLP-1 component counters this in clinical observation.

Triple agonist: GLP-1 + GIP + glucagon receptors. Glucagon arm uniquely increases caloric expenditure on top of appetite suppression.

1. Retatrutide
2. Incretin and appetite-regulating receptors
3. Slowed gastric emptying and altered satiety signalling
4. Energy-balance and glycaemic research endpoints

A plain-English read on how much published evidence currently exists for Retatrutide. These ratings describe the volume and maturity of the literature — not effectiveness, safety, or suitability for any use.

Current limitations: most compounds in this category are studied in preclinical or small-sample settings. Absence of large controlled human trials is the single biggest limitation to keep in mind when reading any summary of Retatrutide.

Lyophilized compounds are supplied as a dry powder. Concentration is simply the total amount in the vial divided by the volume of bacteriostatic water added:

Concentration (mg/mL) = total mg in vial ÷ mL of diluent added

Commonly supplied vial sizes

10mg vial

Worked concentration example

10mg + 2mL BAC water → 5mg/mL On U-100 insulin syringe:

• • 4 units = 1.0mg
• • 8 units = 2.0mg (common starting dose)
• • 16 units = 4.0mg
• • 24 units = 6.0mg
• • 48 units = 12.0mg

Run your own numbers with the reconstitution calculator — it converts vial size and diluent volume into mg/mL and mcg/mL.

The figures below are reported here descriptively, because they are the values most frequently cited in publicly available research literature and reference material. They are not instructions, not a protocol, and not a recommendation. These compounds are supplied for laboratory research use only and are not approved by the FDA for human consumption.

Commonly cited amounts

Start: 2mg weekly × 4 weeks. Titrate by 2mg every 4 weeks. Common range: 4–12mg weekly.

Commonly cited frequency

Once weekly, subcutaneous

Commonly cited study duration

12–24+ weeks. Often run alongside aggressive lifestyle protocol due to rapid loss.

Peptides are supplied freeze-dried because peptide bonds degrade far faster in solution than in a dry state. Understanding storage is part of understanding why the powder form exists at all.

• •Lyophilized powder: stored refrigerated, typically stable for months to years.
• •Reconstituted solution: refrigerated at 2–8°C, generally discussed as stable for roughly 30–60 days.
• •Heat and direct light accelerate degradation — vials are kept cool and dark.
• •Reconstituted material is not re-frozen; ice crystal formation disrupts peptide structure.
• •Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, which is what allows multi-day storage after reconstitution.

More detail in the storage & handling guide and how peptide quality is evaluated.

• •Obesity and weight management (phase 3)
• •Type 2 diabetes
• •Non-alcoholic fatty liver disease (NAFLD/MASH)
• •Cardiovascular outcomes (investigational)
• •Energy expenditure and metabolic rate research
• •Combination metabolic therapy

Retatrutide is the most-anticipated next-generation GLP-1 peptide in online metabolic discussion. The phase 2 results — average weight losses substantially exceeding Semaglutide and Tirzepatide — drove intense attention. Conversations focus on whether the effect translates to phase 3, on side-effect profile (which appears broadly similar to other incretin therapies but with additional glucagon-related considerations), and on when it might become commercially available. It is heavily compared to mazdutide and survodutide, the other emerging triple/dual glucagon-containing compounds.

“The triple-threat metabolic peptide.”

Retatrutide is discussed as a standalone in most online conversation because its triple mechanism already covers what people would otherwise try to stack. In research speculation, people occasionally discuss it alongside amylin analogs like Cagrilintide for additive satiety, but no established protocols exist.

Retatrutide is an investigational once-weekly triple agonist of the GLP-1, GIP, and glucagon receptors developed by Eli Lilly. Its phase 2 trial produced some of the largest non-surgical weight-loss results ever recorded, making it the most-anticipated next-generation metabolic peptide and the leading benchmark for the post-tirzepatide era.